Stock POLYMED POLY MEDICURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Poly Medicure Limited NSE India S.E.

Equities

POLYMED

INE205C01021

Market Closed - NSE India S.E.
Other stock markets
 07:42:31 2024-04-30 am EDT 		5-day change 1st Jan Change
1,643 INR +0.13% Intraday chart for Poly Medicure Limited +7.15% +10.29%
Feb. 02 Transcript : Poly Medicure Limited, Q3 2024 Earnings Call, Feb 02, 2024
Jan. 31 Poly Medicure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 61.64 times its estimated earnings per share for the ongoing year.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
POLY MEDICURE LIMITED Stock Poly Medicure Limited
+10.29% 1.89B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.54% 186B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.85% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.26% 67.44B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.39% 50.03B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.82% 47.81B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.79% 41.03B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.49% 26.85B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.65% 25.82B
A-
TERUMO CORPORATION Stock Terumo Corporation
+16.55% 24.74B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. POLYMED Stock
  4. POLYMED Stock
  5. Ratings Poly Medicure Limited